Results 241 to 250 of about 17,151,553 (293)
Some of the next articles are maybe not open access.

No benefit of faecal microbiota transplantation for IBS-D

Drug and Therapeutics Bulletin, 2020
Abstract Review of: Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4:675–85.
openaire   +2 more sources

▼ Eluxadoline for IBS-D

Drug and Therapeutics Bulletin, 2017
Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal problem characterised by intestinal pain and associated alterations of defecation and/or bowel habit (constipation: IBS-C or diarrhoea: IBS-D). 1,2 Opioid receptors in the gut have a role in gastrointestinal motility ...
openaire   +2 more sources

Editorial: ondansetron for patients with IBS‐D and bowel‐predominant symptoms

Alimentary Pharmacology & Therapeutics, 2023
LINKED CONTENTThis article is linked to Gunn et al papers.
openaire   +2 more sources

Evaluation of treatment continuation with alosetron by IBS-D severity criteria

Current Medical Research and Opinion, 2012
This article evaluates the characteristics and treatment patterns of female patients with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who were treated with alosetron under a risk management program.Patients prescribed alosetron (2002-2009) and who voluntarily enrolled in the follow-up study were evaluated.
Jean Paul, Nicandro   +2 more
openaire   +2 more sources

Perhaps it is time to rethink IBS-D

Scandinavian Journal of Gastroenterology, 2011
To the Editor: Diarrhea predominate irritable bowel syndrome (IBS-D) currently constitutes the largest sub-category of IBS causing a significant emotional and economic impact [1].
openaire   +2 more sources

Dilemma in post-IBD patients with IBS-D symptoms: A 2020 overview

Expert Review of Gastroenterology & Hepatology, 2020
Inflammatory bowel disease (IBD) patients in apparent clinical remission who present with irritable bowel syndrome (IBS)-like symptoms pose a diagnostic and therapeutic dilemma that is called post-IBD IBS. When associated with a diarrheal IBS presentation, this clinical syndrome is known as post-IBD IBS-D.We review and describe the literature regarding
Mukaddes, Tozlu   +3 more
openaire   +2 more sources

Functional impact of IBS-D microbiota on the gut-brain axis

Brain, Behavior, and Immunity, 2015
Irritable Bowel Syndrome (IBS) is a common disorder characterized by altered gut function and frequent psychiatric co-morbidity. Although altered intestinal microbiome profiles have been documented, their relevance to the clinical expression of IBS is unknown.
G. De Palma   +18 more
openaire   +1 more source

Is Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) a Myth?

Medical Research Archives, 2022
The prevalence of Diarrhea Predominant Irritable Bowel Syndrome (IBS D) and chronic diarrhea has been one of the most troublesome diagnoses inflicting approximately 5% of the population annually. These entities have always perplexed physicians that attempt to offer relief to millions of sufferers. Because of the magnitude of the problem, physicians and
openaire   +1 more source

Revival of 5-HT3 antagonism as treatment of IBS-D?

Gut, 2014
While drug development for chronic constipation and IBS with constipation has moved ahead with the marketing of prucalopride and linaclotide in many countries, the development of agents for functional diarrhoea and IBS-D has been more troubled. With the limited availability of the serotonin (5-HT)3 antagonist alosetron, the global market of drugs for ...
openaire   +2 more sources

Diarrhea Predominant Irritable Bowel Syndrome (IBS-D): Fact or fiction

Medical Hypotheses, 2011
Diarrhea Predominant Irritable Bowel Syndrome IBS (IBS-D) and functional diarrhea constitute 50% of cases treated by gastroenterology specialists and a significant proportion of those treated in a primary physicians practice. The size of the problem and the difficulty in successfully addressing these entities has frustrated patients and physicians ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy